Fig 1: The correlations of biochemical parameters in the caudate and putamen of patients with diseases and disease progression.(A) PAR concentration in the caudate of PDD vs. disease progression. (B) TREM2 concertation in the putamen of PDD vs. disease progression. (C) TSPO density in the putamen of PDD vs. disease progression. (D) PAR concentration in the caudate of LBDs vs. disease progression. (E) TREM2 concentration in the putamen of LBDs vs. disease progression. (F) 8-oxo-dG level in the putamen of AD vs. disease progression. (G) MPO concentration in the caudate of AD vs. disease progression. *P < 0.05, **P < 0.01. Sample size: PD, n = 10; PDD, n = 8; DLB, n = 10; AD, n = 27. 8-oxo-dG: 8-Oxo-7,8-dihydro-2'-deoxyguanosine; AD: Alzheimer disease; DLB: dementia with Lewy bodies; LBDs: Lewy body diseases; MPO: myeloperoxidase; PD: Parkinson disease; PDD: PD dementia; PAR: poly (ADP-ribose); rs: Spearman’s rank correlation coefficient; TREM2: triggering receptors expressed on myeloid cell 2; TSPO: translocator protein.
Fig 2: The correlations between PD stage and biochemical parameters in the putamen of patients with LBD.(A) PAR concentration (pM/g). (B) TREM2 concentration (ng/g). *P < 0.05. rs: Spearman’s rank correlation coefficient. LBDs: Lewy body diseases; PAR: poly (ADP-ribose); PD: Parkinson disease; TREM2: triggering receptors expressed on myeloid cell 2.
Supplier Page from Biomatik for Human Triggering Receptor Expressed On Myeloid Cells 2 (TREM2) ELISA Kit